Media thread, page-26

Morning Quiltman & All,

I just watched the video & yes agree with your post Quiltman. Thanks to Hedrox for posting this & the articles.

Very insightful if you marry up the article with Craig & the interview with Niall. I picked up also that he was being incredibly careful about what he said, not wanting to let the cat out of the bag in regards to Conneqt Band - but we have some very good clues there. Below quotes from the article:




In regards to this in your post above

“Any partnerships in the next 12 months will be orientated towards market launches.
- Be it pharma, or retail type partnerships.
- Our CONNEQT ecosystem fits well into the clinical trial setting”

I think Niall said CROs in there as well (contract research organisations) that all Pharma clinical trials are run through & supply all the equipment also, what I have been talking about in recent posts.

In regards to Pharma & CROs this is just an example, recently Bayer gained FDA approval for Finenerone in diabetic kidney disease for patients at risk of cardiovascular disease (CVD). The connection between diabetes, CKD & CVD is very big in the cardiology space at present & also for SGLT2 class of drugs.

Like these, Bayer will now go for heart failure approval & are running a large Ph3 (~5500 patients) in HF patients & a further trial for non diabetic CKD. They are also running trials in Paediatrics as well.

https://media.bayer.com/baynews/baynews.nsf/id/68659FC25DB9F786C125878B00501B1E?open&ref=irrefndcd

This is a massive ongoing clinical programme & then that will most likely continue on with Ph4 post market trials.

This is only one Pharma running massive clinical programmes in this space, others are J&J, AstraZeneca & Eli Lilly.

So this just reinforces CardieX strategy to validate & obtain Gold Standard FDA approval for our technology.

These things take time, but are entirely necessary for technology to be used in the right places & allows for further validation of the technology with Pharma trials (monitoring benefit on drug etc) which is like a companion diagnostic tool.

Then there are the healthy people outside of a target demographic that want to look after their cardiac health, so consumers, to prevent the above with CONNEQT.

Mobvoi as well - imminently, but that will be up to them & their own marketing strategies.

Very exciting stuff & just my thoughts.

GLTAH